COLD AGGLUTININ DISEASE (CAD) IS
 ABOUT MORE THAN AVOIDING THE COLD,

  IS CHRONIC HEMOLYSIS
   IMPACTING YOUR
    PATIENTS?

CAD is a rare type of autoimmune hemolytic anemia with potentially serious acute and chronic consequences1

CAD can have a profound impact on daily life and patients are faced with the threat of severe events.2,3 Learn more about the symptoms they live with, the potential risks they face, and the data that highlight the seriousness of CAD.

Icon of question mark

Patients are burdened
by more than
just anemia

Icon of checklist

Understand criteria
to diagnose CAD
in patients

Icon of exclamation point

CAD can
impact patients'
lives

Sanofi is committed to CAD awareness

CAD=Cold Agglutinin Disease.
References: 1. Berentsen S, Beiske K, Tjønnfjord GE. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology. 2007;12(5):361-370. doi:10.1080/10245330701445392 2. Broome CM, Cunningham JM, Mullins M, et al. Increased risk of thrombotic events in cold agglutinin disease: a 10‐year retrospective analysis. Res Pract Thromb Haemost. 2020;4(4):628-635. doi:10.1002/rth2.12333 3. Mullins M, Jiang X, Bylsma LC, et al. Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization. Blood Adv. 2017;1(13):839-848. doi:10.1182/bloodadvances.2017004390